Eli Lilly & Co: Pay

Eli Lilly & Co paid its 5 named executives $80.4M in total in FY2025 (Dec). CEO David A. Ricks was paid $36.7M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

David A. RicksChair, President, and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Daniel M. Skovronsky, M.D., Ph.D.Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Anat HakimExecutive Vice President, General Counsel and Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years
Lucas MontarceExecutive Vice President and Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Jake Van NaardenExecutive Vice President and President, Lilly Oncology and Head of Corporate Business Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
FY2021 (Dec)
5 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 6 peers with pay on file was $24.2M. The CEO of Eli Lilly & Co was paid $29.2M, 21% above the median.

  1. 1Eli Lilly & Co
  2. 2Pfizer
  3. 3Amgen
  4. 4Johnson & Johnson
  5. 5Biogen
  6. 6Bristol Myers Squibb
  7. 7AbbVie
  8. 8AstraZenecaNot disclosed
  9. 9GileadNot disclosed
  10. 10GlaxoSmithKlineNot disclosed
  11. 11MerckNot disclosed
  12. 12NovartisNot disclosed
  13. 13Novo NordiskNot disclosed
  14. 14RocheNot disclosed
  15. 15SanofiNot disclosed
  16. 16TakedaNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.